Monsenso A/S (MONSO) Fair Value & Analysis
Healthcare · DK · Market cap 15.8M DKK
Fair value as of: Jun 24, 2026
Analysis
Monsenso A/S (MONSO) currently trades at kr 0.4840, while our model-based Fair Value estimate is kr 0.4700 — implying the stock looks roughly 2.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Monsenso A/S develops and sells digital health solution for the treatment of depression, bipolar disorder, anxiety, schizophrenia, borderline personality disorder, and addiction and substance abuse in Denmark. The company offers Monsenso app for individuals that collects patient-reported and sensor data providing insights into symptoms, adherence, and outcomes. It also provides Monsenso solution, a software as a medical device for mental health professionals application that has data collection, direct messaging, visualization and feedback, psychoeducation and cognitive behavioral therapy, medication reminders, task reminders, consultation prepration, and platform integration that allows monitor patients remotely. In addition, the company offers Monsenso app for carers. Monsenso A/S was incorporated in 2013 and is based in Frederiksberg, Denmark.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Monsenso A/S (MONSO) undervalued?
What is the fair value of MONSO?
What is the quality score of MONSO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.